Search

everythinglearnresearchcommunity

for

Search:↓

JAK inhibitors help hair regrowth but not fully effective for androgenetic alopecia.

Cutaneous lupus can cause permanent hair loss by damaging hair follicles.

5α-reductase inhibitors and alpha-1 adrenergic antagonists together effectively treat benign prostatic hyperplasia, with long-term benefits.

5-alpha reductase inhibitors slightly increase the risk of sexual and mood side effects, and breast growth in men.

New tests detect finasteride and dutasteride in urine quickly and easily.

Topical calcineurin inhibitors, especially 0.1% tacrolimus ointment, are effective and well-tolerated for treating cutaneous lupus erythematosus but require more research for standard treatment guidelines.

TNFα inhibitors are effective and well-tolerated for treating severe scalp cellulitis.

Skin problems like acne, dry skin, and nail and hair changes are common in patients taking EGFR inhibitors.

Juniperus plants contain compounds with potential for developing various medical treatments.

Pill organizers and cutters can help with taking medication regularly but may affect the medication's effectiveness and safety.

Drugs like PDEI may help hair disorders like AGA.

Vitamin D may help regulate cholesterol and influence prostate cancer development.

New JAK inhibitor drugs show promise for treating skin diseases but need more research on safety and effectiveness.

In 2017, Spanish dermatologists most often prescribed minoxidil and finasteride for male hair loss, and minoxidil and oral contraceptives for premenopausal female hair loss.

Certain inhibitors applied to the skin can promote hair growth by maintaining a key hair growth signal.

Using CDK inhibitors on rats showed a reduction in chemotherapy-caused hair loss, but later experiments could not repeat these results.

Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.

Certain leukemia drugs can cause severe skin reactions that may require stopping treatment.

Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.

Taking 5-Alpha Reductase Inhibitors before bladder removal surgery might make high-grade bladder tumors less aggressive.

JAK inhibitors help hair regrowth in alopecia areata but have a high risk of side effects.

Biologics and JAK inhibitors may improve treatment for scarring alopecias.

JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.

Medicaid coverage for alopecia areata treatments is inconsistent and often limited.

Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.

New drugs targeting the JAK-STAT pathway show promise for treating inflammatory skin diseases.

Proteasome inhibitors are promising treatments for various cancers, autoimmune diseases, and other conditions.

Selective non-steroidal inhibitors of 5α-reductase type 1 can help treat DHT-related disorders.

Chitosan-coated nanoparticles improve skin delivery of hair loss treatments with fewer side effects.

Certain drugs are effective for skin conditions like psoriasis, vitiligo, and hair loss.